Landmark Dutch appeal court decision reduces risk of third-party damages against pharma patentees

The appellate ruling overturns a recent lower court judgment which exposed life sciences IP plaintiffs to significant additional dangers from health insurer lawsuits

Get unlimited access to all IAM content